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Abstract: The flavivirus envelope protein domain III (EDIII) was an effective immunogen against
dengue virus (DENV) and other related flaviviruses. Whether this can be applied to the Zika virus
(ZIKV) vaccinology remains an open question. Here, we tested the efficacy of ZIKV-EDIII against ZIKV
infection, using several vaccine platforms that present the antigen in various ways. We provide data
demonstrating that mice vaccinated with a ZIKV-EDIII as DNA or protein-based vaccines failed to raise
fully neutralizing antibodies and did not control viremia, following a ZIKV challenge, despite eliciting
robust antibody responses. Furthermore, we showed that ZIKV-EDIII encoded in replication-deficient
Chimpanzee adenovirus (ChAdOx1-EDIII) elicited anti-ZIKV envelope antibodies in vaccinated mice
but also provided limited protection against ZIKV in two physiologically different mouse challenge
models. Taken together, our data indicate that contrary to what was shown for other flaviviruses like
the dengue virus, which has close similarities with ZIKV-EDIII, this antigen might not be a suitable
vaccine candidate for the correct induction of protective immune responses against ZIKV.
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1. Introduction
The Flavivirus genus includes a broad range of pathogenic viruses, some of which are transmitted
by the bite of infected hematophagous arthropods [1]. These viruses, including dengue (DENV), yellow
fever (YFV), and West Nile (WNV) among others, are the causal agents of a wide variety of conditions
that include mild, severe, and fatal hemorrhagic and neurological diseases [2–4]. Until recently, the Zika
virus (ZIKV) was a relatively unknown member of the group, and before the Pacific Island epidemics
in 2013 and 2014, ZIKV infections were mostly mild and sporadically reported in Africa [5]. Following
the 2015 epidemic in Brazil, ZIKV reached a global distribution, geographically overlapping with
DENV, and is now associated with neurotropic disease [6] and congenital Zika syndrome [7].
Like other flaviviruses, ZIKV is a single-stranded, positive-sense RNA virus with a host-derived
double-layered lipid envelope. Its genome encodes a single viral polyprotein that is co- and
post-translationally processed into 10 mature viral proteins [8]. The capsid (C), pre-membrane (prM),
and envelope (E) proteins are structurally required to form a viral particle; while NS1, NS2a, NS2b,
NS3, NS4a, NS4b, and NS5, perform non-structural functions, such as polypeptide post-translational
processing and RNA replication. The viral surface is covered by 180 copies of E, which are arranged in
90 antiparallel dimers and distributed in a herringbone configuration [9,10]. Each copy of the E protein
folds into a rod-like structure and is composed of three structural domains—domains I and II (EDIDII)
form an elongated finger-like structure that expands distally into a glycine-rich, highly-hydrophobic
fusion loop (FLE), which is conserved in all flaviviruses and serves a fundamental role in initiating
infection [11]. Contrary to EDIDII, the Ig-like domain III (EDIII) is highly variable and has been
described as the putative site for host cell-receptor binding [12].
Similar to other flavivirus infections, the E protein is the main target of the antibody response
against ZIKV [13–15]. Although neutralizing epitopes have been identified in all three E domains
for several flaviviruses [16–19], the immune response following infection is heavily dominated
by anti-EDIDII antibodies, most of which target the FLE and tend to be poorly neutralizing and
highly cross-reactive [20,21]. Conversely, due to the high variability and function of the domain,
anti-EDIII antibodies are usually highly specific and strongly neutralizing [22,23]. Based on these
features, EDIII has been used in several vaccine platforms [24], including recombinant protein-based
vaccines [25], virus-like particles (VLPs) vaccines [26], and genetic vaccines such as DNA- [27–29]
and adenovirus-based vaccines [30]. Due to the close structural and biological similarity among
flaviviruses, ZIKV EDIII is a highly attractive target for pre-clinical vaccine developments.
In this study, we tested ZIKV EDIII-based vaccines candidates using different immunization
platforms, including DNA-, viral-vectored (adenovirus), and recombinant protein-based approaches in
mice. Our data suggest that, contrary to other flaviviruses, the polyclonal anti-EDIII response is not
sufficient to confer protection in the context of ZIKV infection. These results open up an exciting new
avenue for the further exploration of ZIKV EDIII antigenic features in ZIKV biology and vaccinology.
2. Results
2.1. EDIII-CH3 DNA-Based Immunization Induces Poorly Neutralizing Antibody Responses
We previously showed that an antigenic design comprised of the EDIII domain from all four DENV
serotypes, C-terminally fused to the dimerizing constant domain 3 of the human IgG heavy chain
(γCH3), not only promotes efficient secretion of properly-folded EDIII from transfected mammalian
cells, but also induces robust long-term virus-specific neutralizing antibody responses in mice,
when administered as a gene gun-mediated DNA vaccine [28]. Here, we decided to build on that
concept and apply it to develop a DNA and a protein-based vaccine against ZIKV. The EDIII sequence
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from the reference ZIKV African strain MR-766 (amino acids 300–421 of the full E protein) was initially
selected due to the availability of the homologous ZIKV strain, to perform functional assays. This strain
has gone through multiple passages in mice, and maintains virulence in this animal model [31,32].
Codon optimized for mammalian expression, was cloned into a pVax expression vector between a
human Ig-derived secretion leader peptide (sec) [33] and the dimerizing γCH3 domain. The SV5 tag
(GKPIPNPLLGLD) was also included to facilitate detection and purification of the fusion protein
(EDIII-CH3) (Figure 1a, left panel). Anti-SV5 tag antibodies could be induced upon vaccination but
these were not assessed as they were not part of the ZIKV DIII antigen. Since antigen availability is of
paramount importance in genetic immunizations [28,34], expression and secretion of the protein was
tested in transiently transfected HEK293T cells, which revealed a highly efficient secretory phenotype
(Figure 1a, right panel).
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Figure 1. Functional immunogenicity of a DNA vaccine expressing ZIKV EDIII. (a) Schematic
representation of constructs encoding ZIKV EDIII fused to the dimerizing γCH3 domain, based on an
African strain of the Zika virus (ZIKAAF) (left) and Western blot (anti-SV5) of cellular extracts (E) and
supernatants (S) from HEK293T cells transfected with the indicated constructs. Soluble ZIKV E protein
from the supernatant of cells transfected with a plasmid construct expressing the SV5-tagged protein
is shown for size comparison. (b) Pooled sera from DNA immunized mice were tested for ELISA
reactivity on ZDIII-coated plates; the dashed line marks the detection limit of the assay. (c) Antibody
titers from the curves shown in (b). (d) Foci reduction neutralization test (FRNT) of ZIKV on Vero cells
with pooled sera from mice immunized with ZDIII-CH3.
For the DNA immunizations, three groups of six female BALB/c mice were immunized by
intradermal gene gun delivery of the plasmid DNA encoding the EDIII-CH3 protein. Each mouse
received three doses of DNA (1 µg dose/animal) at 15 days intervals; sera were collected two weeks
after completion of the protocol and pooled for analysis. Sera dilutions showed that all mice developed
anti-ZIKV E antibody responses that were able to bind ZIKV E in ELISA (Figure 1b). As expected,
anti-EDIII titers were detected in all three groups of immunized animals with mean titers ranging
from 1 × 104 to 2.25 × 104 (Figure 1c). We then used the Foci Reduction Neutralization test (FRNT) to
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measure the neutralizing activity of the sera in vitro. Surprisingly, although all groups showed some
degree of neutralizing activity, none reached 100% neutralization of ZIKV, and the FRNT50 titers were
detected only in one group (Figure 1d). These results indicate that, despite being able to drive a robust
anti-EDIII response, the anti-EDIII antibodies induced by DNA-immunization showed a low ZIKV
neutralizing activity.
2.2. EDIII-CH3 Protein-Based Immunization Induce Poorly Neutralzsing Antibody Responses
To rule out that the low neutralizing activities of the anti-EDIII responses were due to a factor
inherent to the DNA immunization technique (i.e., altered in vivo production of the antigen, low levels
of protein availability, etc.), we produced and purified the EDIII-CH3 antigen and administered it as a
protein-based vaccine. EDIII-CH3 was purified from the supernatant of transfected Expi293F cells with
anti-SV5 agarose affinity gel; as expected from its design, the protein was obtained as a non-covalent
dimer that is disassociated upon heat treatment (Figure 2a).
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Figure 2. Functional immunogenicity of a subunit vaccine expressing ZIKV EDIII (a) SDS-PAGE of the
purified protein. Cell supernatant (Input) and post-purification (Output) samples were analyzed in
SDS-PAGE, following heat treatment (or not). Black arrows show the position of the monomeric (+heat)
and dimeric (−heat) EDIII-CH3. (b) Sera from immunized mice were tested for ELISA reactivity on
ZEDIII-coated plates; the dashed line marks the limit of the assay. (c) Antibody titers from the curves
shown in (b). (d) Foci reduc ion neutralization test (FRNT) of ZIKV n Vero cells with sera from mice
immunized with ZEDIII-CH3.
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Six BALB/c mice were immunized with 10 µg of the EDIII-CH3 protein using 1% ALUM MPLA
(monophosphoryl lipid A) as adjuvant. Each mouse received, subcutaneously, three doses of the
protein at 15 days intervals, and sera were collected two weeks after the third dose. As shown in
Figure 2b, all mice developed strong anti-EDIII responses, which were higher in titer when compared
to the gene-gun immunized mice (Figure 2c). As a result of the higher antibody titer and in contrast to
results obtained for the DNA vaccine, FRNT50 titers were detected in all six mice; although, as before,
none reached 100% neutralization of the virus (Figure 2d).
The protective efficacy of the EDIII-CH3 protein-based vaccines was further assessed in Interferon
Type-I Receptor knockout mice, A129, which are highly susceptible to the ZIKV infection [35]. In this
case, 8 mice were immunized with the EDIII-CH3 protein, following the same protocol and were
challenged with 104 PFU ZIKV PRVABC59 strain. Availability of an Asian-origin virus permitted the
efficacy assessment of a heterologous challenge in mice vaccinated with an African lineage antigen.
Similar to the control group (Figure 3a), protein-immunized mice were not able to contain ZIKV
infection, as demonstrated by the increasing viral load titers detected in all mice after the challenge
(Figure 3b), even though the peak of the viral titers was detected at a later time (Figure 3c). An analysis
of the area under the curve (AUC) did not show significant differences (218,197 with 95% CI 23,273 to
413,121 for EDIII-CH3 vs. 421,938 with 95% CI 164,150 to 679,727 for the control, p = 0.2344) Failure
to prevent viral infection was not related to a diminished response to the EDIII-CH3 antigen, as all
pre-challenge sera showed consistent anti-EDIII antibody responses (Figure 3d) with a mean reciprocal
titer of >4 (Figure 3e).
2.3. Adenoviral Vaccine Design Carrying ZIKV EDIII
To determine if the poorly neutralizing responses obtained with the DNA and protein-base
EDIII-CH3 vaccines were due to a problem of antigenic design or rather due to an incapacity of
the anti-EDIII polyclonal response to neutralize ZIKV effectively, we next evaluated a replication
deficient chimpanzee adenoviral vector (ChAdOx1) as an immunization platform. Based on a
previously described prME ∆TM-encoding adenoviral vectored- ZIKV vaccine [36], we constructed
a ChAdOX1 encoding a codon-optimized ZIKV EDIII sequence (Figure 4a) cloned between the tPA
signal sequence and a transcription termination sequence (Figure 4b). We created a consensus sequence
from Asian lineages (ZIKVAS) to maintain consistency with a previous publication, whilst expanding
our observations beyond the African strain-based designs that are dimeric, to a monomeric antigen
based on Asian lineages. We then tested the ability of the ChAdOx1-EDIII vaccine to protect BALB/c
mice upon an intravenous ZIKV challenge of 100 PFU, four weeks after a single immunization
(1 × 108 IU/mouse), using an Asian-lineage of ZIKVAS, ZKV2015 (Figure 4c). ZIKV challenge in naïve
mice (n = 5) displayed a typical onset of viremia after challenge, with a peak by day 3 (Figure 4d)
and the clearance of viral load in blood by day 7. Similar results to that of the EDIII protein vaccine
were observed, as ZIKV replication was detected in both vaccinated and control mice, albeit all mice
immunized with ChAdOx1-EDIII showed signs of protection as viral loads were significantly lower
than those obtained in the control group (Figure 4e). An analysis of area under the curve (AUC)
indicated that the vaccinated group displayed significantly better protection than the mock vaccinated
group (105,567 with 95% CI 1,425-209,709 for EDIII vs 363,416 with 95% CI 244,574 to 482,257 for the
control, p = 0.0126). Interestingly, a delay of viral peak at day 4 was observed in 2 out of 5 mice and
complete protection with absence of viremia was observed in one mouse. Assessment of anti-EDIII
antibodies in the pre-challenge sera, revealed high titers of anti-ZIKV E antibodies in all the animals
vaccinated with ChAdOx1-EDIII (Figure 4f,g). Overall, the data obtained from the EDIII-CH3 DNA,
subunit and viral vectored vaccines suggest that ZIKV EDIII confers suboptimal protection upon a
ZIKV challenge.
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Figure 3. Assessment of protective efficacy induced by protein-based EDIII vaccine. Naïve (a) and
vaccinated (b) mice (n = 8) were intravenously challenged at four weeks after vaccination with 104 PFU
of ZIKV- PRVABC59 strain. Upon ZIKV challenge, the viral load was monitored for up to seven days.
Graphs show days post-challenge on the x-axis versus viral load on the y-axis. Continuous blue and
red lines represent one mouse each for each of the control and vaccinated groups. (c) Peaks of viral
titers for each individual mouse and for each group. (d) Sera from immunized mice were tested for
ELISA reactivity on ZDIII-coated plates; the dashed line marks the limit of the assay. (e) Antibody
titers from the curves shown in (b). *** p < 0.001
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2.4. Immunogenicity and Efficacy of ChAdOx1-EDIII in A129 Mice
The ChAdOx1-EDIII vaccine efficacy was additionally assessed in A129 mice undergoing a
ZIKVAF heterologous-lineage challenge [35]. Control, mock-vaccinated mice displayed a typical onset
of infection after the ZIKV challenge, characterized by an initial increase in body temperature, followed
by a drastic decrease (Figure 5a, blue line). In comparison, the ChAdOx1-EDIII vaccine prevented an
increase in temperature between days 5–7 (Figure 5a, red line), but displayed the rapid temperature
decrease shown in the mock control group. Consistent with the ZIKV challenge model, animals
vaccinated with the ChAdOx1 mock control, presented a decrease of body weight (Figure 5b) and
clinical symptoms (Figure 5c, blue line), reaching the humane endpoint criteria (80% body weight)
between day 7 and 8. In agreement with the previous experimental observations, mice receiving the
ChAdOx1-EDIII failed to control the infection and met humane endpoints between day 7 (n = 1/6)
and day 8 (n = 5/6) (Figure 5d, red line). Taken together, we observed coherent results indicating that
the ChAdOx1-EDIII vaccine failed to elicit protective immunity in a Type I interferon deficient mouse
challenge model.
Measurement of viral load in tissues from euthanized A129 mice indicated that both mock control
and ChAdOx1-EDIII vaccinated mice had similar high brain viral loads detectable at day 8 (Figure 5e,
Brain). Similar findings were obtained by in-situ hybridization (ISH) in brain tissue (Figure 5f), with the
presence of ZIKV in both groups but a trend towards lower levels in the ChAdOx1-EDIII group.
Notably, absence of viral RNA was evident in the ovaries of most ChAdOx1-EDIII vaccinated
group (5/6 showed RNA absence), but high levels were detected in the mock control group (Figure 5e,
ovaries). Additional ISH in the ovaries demonstrated the presence of ZIKV in the unrelated vaccinated
group and a lower but existing burden in the ovaries from the ChAdOx1-EDIII vaccinated group (1 out
of 6 mice) (Figure 5f). Similarly, RNAemia at the time of culling (day 7–8) was undetectable in the
ChAdOx1-EDIII group and was positive in the mock control groups (Figure 5e, blood). Finally, viral
loads in the spleen were similar in both groups with a non-significant trend towards decrease in the
ChAdOx1-EDIII group (Figure 5e, spleen). Histological analysis was performed to assess the extent of
tissue damage brought about by the ZIKV challenge in both vaccinated groups (Table 1).
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Table 1. Histology analysis in immunized A129 mice after ZIKV infection.
Vaccine Animal ID HistologyID
Culled by
Day
Diffusely
Scattered
Nuclear
Debris
Lymphocytic
Perivascular
Cuffing
Diffusely
Scattered
PMNs
Degenerating
Neurons-
Hippocampus
Patchy,
Meningeal
Infiltration by
Inflammatory
Cells
Poorly Defined
Areas of White
Pulp with Large
Mononuclear
Cells
EMH +/−
Apoptosis
Mature
PMNs in
Red Pulp
Sinuses
Vehicle
31,371 732/17 7 Mild Mild WNL WNL Moderate Mild Moderate Mild
33,333 733/17 7 Mild Minimal Minimal WNL Minimal Mild Moderate Mild
31,110 734/17 7 Minimal Minimal WNL Minimal Minimal Mild Moderate Minimal
13,509 735/17 7 Minimal Minimal WNL WNL Mild WNL Moderate Mild
31,127 736/17 6 WNL Minimal WNL WNL Minimal WNL Moderate Mild
13,035 737/17 7 Moderate Moderate Minimal Moderate Moderate Mild Moderate Minimal
ChAdOx1
EDIII
31,764 714/17 8 Moderate Moderate WNL Marked Moderate WNL Moderate WNL
12,300 715/17 8 Mild Mild WNL Moderate Moderate WNL Moderate Minimal
31,303 716/17 8 Mild Moderate WNL Minimal Moderate Minimal Moderate Mild
31,131 717/17 8 Mild Mild Minimal WNL Moderate Minimal Moderate Mild
13,219 718/17 7 Minimal Moderate WNL Minimal Moderate WNL Moderate Minimal
31,398 719/17 8 Minimal Moderate WNL Minimal Moderate Minimal Severe Mild
Reference
13,657 690/17 21 WNL WNL WNL WNL WNL WNL Minimal WNL
12,304 691/17 21 WNL WNL WNL WNL WNL WNL Mild WNL
13,545 692/17 21 WNL WNL WNL WNL WNL WNL Mild WNL
31,609 693/17 21 WNL WNL WNL WNL WNL WNL Mild WNL
15,214 694/17 21 WNL WNL WNL WNL Minimal WNL Mild WNL
13,448 695/17 21 WNL WNL WNL WNL WNL WNL Minimal WNL
ChAdOx1
Mock
31,220 726/17 8 Minimal Moderate WNL Mild Mild Mild Moderate Mild
13,690 727/17 8 Mild Moderate WNL Mild Moderate Minimal Moderate Moderate
34,144 728/17 8 Minimal Mild Mild Moderate Moderate Minimal Severe Mild
13,122 729/17 8 WNL Mild WNL Not present Minimal Not present
12,189 730/17 7 Minimal Mild WNL WNL Moderate Minimal Moderate Mild
13,555 731/17 7 Minimal Minimal Minimal WNL Mild Mild WNL Mild
Vehicle
31,371 732/17 7 Mild Mild WNL WNL Moderate Mild Moderate Mild
33,333 733/17 7 Mild Minimal Minimal WNL Minimal Mild Moderate Mild
31,110 734/17 7 Minimal Minimal WNL Minimal Minimal Mild Moderate Minimal
13,509 735/17 7 Minimal Minimal WNL WNL Mild WNL Moderate Mild
31,127 736/17 6 WNL Minimal WNL WNL Minimal WNL Moderate Mild
13,035 737/17 7 Moderate Moderate Minimal Moderate Moderate Mild Moderate Minimal
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Table 1. Cont.
Vaccine Animal ID HistologyID
Culled by
Day
Diffusely
Scattered
Nuclear
Debris
Lymphocytic
Perivascular
Cuffing
Diffusely
Scattered
PMNs
Degenerating
Neurons-
Hippocampus
Patchy,
Meningeal
Infiltration by
Inflammatory
Cells
Poorly Defined
Areas of White
Pulp with Large
Mononuclear
Cells
EMH +/−
Apoptosis
Mature
PMNs in
Red Pulp
Sinuses
ChAdOx1
EDIII
31,764 714/17 8 Moderate Moderate WNL Marked Moderate WNL Moderate WNL
12,300 715/17 8 Mild Mild WNL Moderate Moderate WNL Moderate Minimal
31,303 716/17 8 Mild Moderate WNL Minimal Moderate Minimal Moderate Mild
31,131 717/17 8 Mild Mild Minimal WNL Moderate Minimal Moderate Mild
13,219 718/17 7 Minimal Moderate WNL Minimal Moderate WNL Moderate Minimal
31,398 719/17 8 Minimal Moderate WNL Minimal Moderate Minimal Severe Mild
Reference
13,657 690/17 21 WNL WNL WNL WNL WNL WNL Minimal WNL
12,304 691/17 21 WNL WNL WNL WNL WNL WNL Mild WNL
13,545 692/17 21 WNL WNL WNL WNL WNL WNL Mild WNL
31,609 693/17 21 WNL WNL WNL WNL WNL WNL Mild WNL
15,214 694/17 21 WNL WNL WNL WNL Minimal WNL Mild WNL
13,448 695/17 21 WNL WNL WNL WNL WNL WNL Minimal WNL
ChAdOx1
Mock
31,220 726/17 8 Minimal Moderate WNL Mild Mild Mild Moderate Mild
13,690 727/17 8 Mild Moderate WNL Mild Moderate Minimal Moderate Moderate
34,144 728/17 8 Minimal Mild Mild Moderate Moderate Minimal Severe Mild
13,122 729/17 8 WNL Mild WNL Not present Minimal Not present
12,189 730/17 7 Minimal Mild WNL WNL Moderate Minimal Moderate Mild
13,555 731/17 7 Minimal Minimal Minimal WNL Mild Mild WNL Mild
Histological lesions were assessed in ChAdOx1-EDIII vaccinated mice and control groups. As a comparison, mice were vaccinated with a reference vaccine consisting of a ChAdOx1 prME
∆TM, which provided 100% protection against the ZIKV challenge. The table shows the day of culling for each mice. For the brain and spleen, 5 and 3 different microscopic measurement
observations were performed, respectively. Scores are within normal limits (WNL) (dark green), minimal (light green), mild (yellow), moderate (dark red), and severe (light red).
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3. Discussion
Following the ZIKV outbreaks in the Pacific Islands in 2013–2014 and Brazil in 2015, virologists
across the world focused their attention and efforts into understanding a pathogen that was relatively
overlooked. The urgent need to develop treatments and vaccines prompted the initial strategies to be
developed, based on known flaviviruses, particularly DENV.
Although most efforts to develop an effective DENV vaccine used the full E protein (either as a
soluble protein or as part of higher structures like VLPs and attenuated/inactivated viruses), there is
also a large body of evidence showing that a vaccine based on the EDIII structure could be used as a firm
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candidate to target flaviviruses. Besides the fact that most anti-EDIII monoclonal antibodies (mAbs)
show high viral neutralizing activities, the rationale for investigating EDIII-based vaccines relies mostly
on its potential to direct the immune response to a virus-specific, biologically relevant and simple
target that is capable of preventing the induction of cross-reacting but poorly-neutralizing anti-FLE
antibodies and, thus, reducing the risk of inducing antibody-dependent enhancement (ADE) [38–40].
Despite the abundance of EDIII-based vaccine candidates that have were developed for other
flaviviruses, to our knowledge the number of similar candidates for ZIKV is scarce and no clinical
trials using ZIKV E-DIII were published. Yang et al. produced a vaccine based on ZIKV E-DIII fused
with the hepatitis B core antigen (HbcAg-zDIII) to form VLPs in Nicotiana benthamiana plants [41],
as well as a refolded EDIII from E. coli [42]. Immunization with the HbcAg-zDIII VLP vaccine in
mice using protocols involving different priming/boost schemes, induced anti-EDIII antibodies and
showed evidence of in vitro neutralization, with no induction of ADE against DENV2 [41]. In a
similar report, Cabral-Miranda et al. developed a VLP-based approach to display ZIKV E-DIII, using a
modified cucumber mosaic virus (CuMVtt-EDIII) [43]; three doses of an adjuvanted CuMVtt-EDIII
vaccine induced high titers of anti-EDIII antibodies but low ZIKV neutralizing activities (FRNT50
titer of <1:100). Interestingly, a single-dose and non-adjuvanted administration of CuMVtt-EDIII or
EDII alone did not show neutralizing efficacy at 21 days after immunization of the BALB/c mice,
but did elicit a high titer of anti-EDIII antibodies, as measured by ELISA. More importantly, given the
discrepancies between in vitro and in vivo data, especially regarding protection from viral infection,
none of the studies described above included a ZIKV challenge model to test the efficacy of the
proposed antigens vaccines.
To further test the suitability of an EDIII-based vaccine to elicit efficacious immunity against
ZIKV, we constructed ZIKV-EDIII-based vaccines using three different vaccine platforms—plasmid
DNA delivered by a gene gun, protein in adjuvant, and adenoviral-vectored vaccines. DNA gene gun
vaccination offers the advantage of a low-cost in vivo delivery of DNA into the skin, allowing the
introduction of the genetic material into cells to encode the antigen of interest. Upon production of the
protein, cells like skin fibroblasts and dendritic cells initiate a systemic immune response. This design
follows our previously reported tetravalent DNA EDIII-based DENV vaccine, which showed that
fusion of the EDIII antigen to the dimerizing CH3 domain of the human IgG heavy chain, improved its
secretion, thus increasing antigen availability, which boost the immune response when compared to
EDIII, which showed lower secretory profiles [28]. As shown by our data, this design also addressed
one of the main criticisms attached to genetic vaccines by bringing the immunogenicity of the candidate
to levels similar to those measured when using equivalent protein-based antigens. Our previous
attempts with the DENV vaccine demonstrated that three 1 µg doses of the EDIII-CH3 DNA vaccine
elicited antibodies with high DENV-neutralizing activities in BALB/c mice. In contrast, although the
EDIII-CH3 DNA vaccine successfully elicited antibodies against ZIKV E in high titers, which were
similar to those induced by an equivalent DENV antigen [28], the virus neutralizing capacity was only
modest and notably, none of the tested sera induced 100% neutralization of ZIKV under the conditions
tested. Given the disparities between the DENV and ZIKV antigens, we speculated that this could be
due to an unexpected compromise regarding antigen secretion or folding in vivo, which could then
lead to a limited response against particular epitopes relevant for exerting neutralization.
To test a different strategy for antigen delivery and circumvent any potential limitation poised
by the in vivo production of the immunogen, we used the same construct to purify the antigen from
mammalian HEK293F cells. In agreement with our DNA-based vaccine, the EDIII-CH3 protein vaccine
elicited high anti-EDIII antibody titers and none of the serum reached 100% ZIKV neutralization at the
lowest dilution tested. To determine if the neutralizing activities induced by the EDIII-CH3 protein
vaccine were sufficient to confer in vivo protection, we challenged vaccinated A129 mice and followed
the course of viral infection. Our data showed that even in the presence of high anti-ZIKV E, none of
the vaccinated mice were able to successfully control viremia.
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To exclude the possibility that the design of the ZIKV EDIII antigen as a CH3-fused dimer
could compromise the response to key neutralizing epitopes, we decided to redesign the vaccine as
a monomeric EDIII protein using an adenovirus-vectored platform that was previously shown to
confer full protection in mice and non-human primates, when using the complete ZIKV E protein as an
antigen [36]. In this context, the ChAdOx1 viral-vectored platform was designed to express ZIKV EDIII
(ChAdOx1-EDIII) and the vaccine was then tested in two different ZIKV challenge models [35,37].
Besides using an Asian strain instead of an African strain of ZIKV, this antigen differs from the
EDIII-CH3 used in the DNA and protein-based vaccines, in the lack of the γCH3 dimerizing domain,
which leads to its secretion as a monomeric single-domain peptide, as opposed to a fusion-protein
non-covalent dimer. Our results demonstrated that a single and non-adjuvanted immunization using
ChAdOx1-EDIII, elicited high anti-ZIKV E antibodies in both BALB/c and A129 mice. Upon ZIKV
challenge, a reduction in ZIKV RNAemia was detected in BALB/c mice, but the vaccine was not able
to elicit complete protection. Likewise, ChAdOx1-EDIII-vaccinated A129 mice experienced weight
loss, temperature-change, and clinical symptoms similar to the mock-vaccinated mice, with detection
of virus in the brain and spleen. Of interest, the only two organs where we found a vaccine-induced
lower ZIKV load was in ovaries and blood.
Our results consistently showed that all three vaccines readily induced anti-EDIII antibodies,
but none was able to completely neutralize ZIKV in vitro and in vivo. Our data indicated that, contrary
to DENV, a polyclonal anti-EDIII antibody response at the concentration, specificity, and avidity
induced by these three vaccines, only had a limited capacity to neutralize ZIKV. Studies have shown
that some anti-ZIKV EDIII mAbs isolated from the ZIKV-exposed patients possess strong neutralizing
activities [44,45] and confer protection through passive immunization into IFNAR (−/−) mice. However,
there is evidence that the frequency of human neutralizing antibodies within the overall polyclonal
response is lower against DIII than against the fusion loop epitope (FLE) within DII. The latter provides
a higher and broader anti-ZIKV neutralization capacity that protect mice against both, African and
Asian–American lineages in non-pregnant and pregnant mouse models, preventing maternal–fetal
transmission, dam infections, and disease [46]. However, this still remains unknown and might not be
sufficient to provide complete protection. Moreover, just as the anti-EDIII response is significantly
stronger and more potent in mice than in humans, the nature of the ZIKV antibody response in mice
and humans might be significantly different, making it difficult to infer or extrapolate data across
species. It should also be considered whether the patients involved in human studies might have had
previous DENV infections that shaped the immune response to ZIKV, leading to anti-EDIII antibodies
with increased neutralizing strength. Zhao et al. isolated mAbs from mice primed with ZIKV and
then boosted with soluble EDIII or ZIKV, with differential binding and neutralization capacities [18].
Of particular interest, mAbs raised in ZIKV-exposed mice and boosted with ZIKV EDIII, could bind
monomeric E but they did not bind to ZIKV particles. The more potently neutralizing anti-EDIII mAbs
(ZV-67 and ZV-54) recognized the lateral ridge (LR) epitope of EDIII and they were able to bind about
66% of the DIII domains in a mature ZIKV. Passive transfer of both ZV-67 and ZV-54, yielded complete
protection upon a ZIKV challenge model in IFN-deficient mice [18]. As the above experiments were
performed in a pre-clinical setting, our results in vaccinated mice showing high titers of anti-DIII
antibodies but low or poor anti-ZIKV efficacy might be due to an enrichment of antibodies recognizing
the EDIII epitopes that are not displayed in infective ZIKV particles. Therefore, it is imperative to design
improved antigens that favor a response against relevant neutralizing epitopes in both the therapeutic
and the prophylactic settings [47]. Further structurally guided studies are needed to inform the design
of relevant immunodominant epitopes to favor the induction of potent neutralizing antibodies. It is
important to mention that, in our work, protein conformation and potentially neutralizing epitopes
exposure could be different between the DNA-encoded protein, the protein sub-unit or the ChAdOx1
platform with the EDIII presentation on native virions, thus raising the need to perform structural
studies using conformation sensitive anti-EDIII antibodies in all expressed proteins. In addition,
while correlates or estimates of protection based on the measurement of neutralizing antibodies are
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established for YFV, WNV, JEV, and TBEV, similar standards of protection are still lacking for DENV
and ZIKV and significantly compromise the analysis and extrapolation of data, blurring the lines
of what is needed for a vaccine to be considered protective and efficient. Here, we reasoned that in
the absence of such standards, the only reliable way to measure the viability of a vaccine candidate
was through its ability to either fully neutralize the virus in vitro or provide sterile protection in
ZIKV challenge models. Despite neutralizing activities being detected in all cases, none of the three
candidates described here comply with this requirement.
To our knowledge, this is the first report that highlight a disparity between the highly immunogenic
nature of ZIKV EDIII and the poor neutralizing capacity of the polyclonal antibody response induced
against ZIKV EDIII, using different vaccine platforms. More in-depth studies of these responses
would significantly increase our knowledge of the effective neutralizing determinants against ZIKV,
which could directly inform the development of improved vaccine candidates to achieve protective
anti-ZIKV responses, while still avoiding the ADE of DENV.
4. Material and Methods
4.1. Animals
Female A129 mice were purchased from a home office approved breeder and supplier
(B&K Universal Ltd., part of Marshall BioResources, Hull, UK).
For the A129 mice vaccinated with the ChAdOx1 vaccine platform, mice were implanted with a
temperature and identity chip upon arrival. During three days’ rest, baseline observations of behavior,
temperature, and weight were recorded.
4.2. Vaccines
For DNA vaccines, animals were immunized by biolistic delivery of 1 µm gold particles coated
with 1 µg of plasmid DNA using Gene Gun technology (Bio-Rad, Hercules, CA, USA), as previously
described [28]. Blood samples were collected at day 90 by sub-mandibular puncture and the mice
subsequently euthanized using CO2 inhalation. De-complemented pooled sera samples (30 min at
56 ◦C) were stored at −20 ◦C until use.
Protein-based vaccine was expressed using the ExpiFectamine™ 293 Transfection Kit (Thermo
Fisher Scientific, Abingdon, UK) and purified using the V5-tagged Protein Purification Gel (Caltag
Medsystems Ltd., Buckingham, UK) following manufacturer’s instructions.
Adenovirus-based vaccines were prepared in Eppendorf tubes individually prepared for each
animal group. Animals were vaccinated in the right hind limb, with 50 µL of vaccine via the
intramuscular route at a dose of 10 E8IU/mouse.
4.3. Animal Ethics
4.3.1. DNA-Based Vaccine
All animal procedures were approved by the ICGEB Animal Welfare Board and the Italian Ministry
of Health (Ministero della Salute) (approved protocol DGSAF0024706) and were conducted by adhering
to institutional and international guidelines for animal experimentation, and in compliance to laws
and policies established in the legislation D. L.vo 26/2014 of the Italian Government.
4.3.2. Protein-Based Vaccine
All animal research related to the protein-based vaccine was approved by the University of
Glasgow Animal Welfare and Ethical Board and was carried out under United Kingdom Home Office
Licenses, P9722FD8E, in accordance with the approved guidelines and under the UK Home Office
Animals (Scientific Procedures) Act 1986 (ASPA).
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4.3.3. Adenovirus-Based Vaccine
All animals and procedures were used in accordance with the terms of the UK Home Office
Animals Act Project License. Immunization and immunogenicity procedures were approved by the
University of Oxford Animal Care and Ethical Review Committee (P9804B4F1).
4.3.4. Pre-Challenge Bleed
One day before challenge, sera was collected from a maximum volume of 100 mL of drawn blood.
4.3.5. Enzyme-Linked Immunosorbent Assay (ELISA) to Quantify Whole IgG
RecombivirusTM Mouse anti-ZIKV envelope protein IgG ELISA kits (Alpha Diagnostic
International, RV-403120-1) were used according to the manufacturer’s protocol. In brief, 96-well plates
coated with the ZIKV envelope protein were equilibrated with 300µL of kit working wash buffer. Serial
dilutions (3-fold) of sera from vaccinated mice were added. Diluted sera were incubated at RT for 1 h,
and after four times washing buffer incubations, 100µL/well of anti-mouse IgG HRP-conjugate working
solution was added for 30 min at room temperature. Plates were washed 5 times and developed
for 15 min at room temperature with 100µL of (TMB) substrate (3,3′,5,5′-tetramethylbenzidine),
then stopped by the addition of 100µL of stop solution. Absorbance was measured at 450 nm on a
microplate reader. ELISA ODs were compared between all vaccinated groups at different sera dilutions.
For ELISA in BALB/c mice before challenge, antibody endpoint titres are the highest reciprocal serum
dilution that resulted in an absorbance >2-fold over the background values, as calculate elsewhere [36].
Anti-Zika envelope antibody concentrations in A129 mice sera before challenge was measured by IgG
ELISA using Zika Env antigen as previously described [48].
4.3.6. Challenge Virus
Mice vaccinated with ChAdOx1-based vaccines were challenged using two different lineages.
Wild-type mice (Figure 4) were challenged with an intravenous injection of 105 vp (equivalent to
102 PFU) of ZIKVAS, consisting of the ZKV2015 (ZIKV BR), as described earlier [36,37]. To extend our
observations, the experiment depicted in Figure 5 used A129 mice undergoing a heterologous challenge
with a ZIKVAF strain, made with 100 PFU ZIKVAF (MP1751) via the subcutaneous (s.c.) route, to mimic
mosquito bite [35]; 40 µL into the right leg and 40 µL into left leg toward the ankle. Mice of the protein
vaccine experiment were challenged with 104 PFU Puerto Rican strain ZIKV (PRVABC59) always by
the s.c. route, which was performed at a different lab from the ChAdOx1 vaccines.
4.3.7. Clinical Measurements
Over the duration of the study, a daily assessment of temperature and weight was made at least
once daily, which included assessment of clinical scores twice a day or more if required during critical
periods of the study, to limit animal suffering as a consequence of the infection.
A numerical value was followed for clinical scores—0 normal; 2 ruffled fur; 3 wasp-waisted,
pinched, hunched or lethargy; 5 labored breathing, rapid breathing, inactive, neurological;
and 10 immobile.
Unnecessary suffering to animals was prevented through the use of humane clinical endpoints
by which animals were culled upon reaching any of the following criteria—lack of movement after
stimulus-like handling; neurological signs indicated by repetitive movement; weight of approximately
15%–20% from original weight.
4.3.8. Sample Collection
Upon meeting humane clinical endpoints or at the end of the study, mice were culled by the
approved methods and blood, spleen, brain, and ovaries were collected at necropsy.
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4.4. PCR Quantification of Viral Load
4.4.1. Protein-Based Vaccine
Viral RNA was extracted from 10 µL of serum sample, using the QIAamp Viral RNA Kit (Qiagen:
Manchester, UK). Real time RT-PCR assay was performed using the One-Step TB Green PrimeScript
RT-PCR Kit II (Perfect Real Time) (TaKaRa) (Saint-German-en-Laya, France), with the following
amplification conditions—42 ◦C for 5 min and 95 ◦C for 10 s, followed by 40 cycles of 95 ◦C for 5 s and
60 ◦C for 34 s. The primers used were ZIKV-F: 5′-GTTGTCGCTGCTGAAATGGA-3′ and ZIKV −R:
5′-CGGGACTCTGATTGGCTGTA-3′. A standard curve was generated from ZIKV RNA extracted
from 10-fold diluted virus stock with known viral titers in triplicates. The developed real-time RT-PCR
assay showed a linear curve with high amplification efficiency and strong correlation (R2 = 0.999,
Slope—3.31).
4.4.2. Adenovirus-Based Vaccine
Samples were homogenized in PBS using ceramic beads in a Precellys (Lutterworth, UK) automated
homogenizer, using a setting of 6 × 5 s cycles of 4500 rpm with a 30 s pause between each cycle. A total
of 100 µL of homogenate was transferred to 300 µL RLT buffer (Qiagen, Manchester, UK) for RNA
extraction; 25 mL blood were processed using RNAprotect tubes, adding 75 µL of PBS to 300 µL of
RLT buffer. After incubation for 10 min, 400 µL of ethanol (70%) were added to the homogenate. The
sample was passed through a Qiashredder (Qiagen, Manchester, UK). RNA from ovary and brain
was obtained using a Biosprint extraction kit (Qiagen, Manchester, UK) and Kingfisher flex system
(ThermoFisher Scientific, Abingdon UK). RNA from spleen and blood was processed using a RNeasy
mini kit (Qiagen, Manchester, UK).
A real-time RT-PCR assay for ZIKV was used to quantify viral RNA. Real-time RT-PCR
was performed using the SuperScript III Platinum One-step qRT-PCR kit (Life Technologies,
Warrington UK). The mastermix (15 µL) consisted of 10 µL of 2x Reaction Mix, 1.2 µL
of PCR-grade water, 0.2 µL of 50 mM MgSO4, 1 µL of each primer, ZIKV 1086
(5′-CCGCTGCCCAACACAAG-3′) and ZIKV 1162c (5′-CCACTAACGTTCTTTTGCAGACAT-3′)
(REF PMID 18680646), both at 18 µM working concentration, 0.8 µL of probe ZIKV 1107-FAM
(5′-AGCCTACCTTGACAAGCAGTCAGACACTCAA-3′) at 25 µM working concentration, and 0.8 µL
of SSIII enzyme mix. A total of 5 µL of template RNA was added to the mastermix to give a final
reaction volume of 20 µL. Cycling conditions used were 50 ◦C for 10 min, 95 ◦C for 2 min, 45 cycles at
95 ◦C for 10 s with 60 ◦C for 40 s, and a final cooling step of 40 ◦C for 30 s. Fluorescence was quantified
at the end of each 60 ◦C step. Analysis was performed using the QuantStudio platform (Applied
Biosystems, Warrington UK).
Virus load was quantified in samples using a dilution series of quantified RNA oligonucleotide
(Integrated DNA Technologies, Leuven, UK). The oligonucleotide consisted of 77 bases of ZIKV RNA
targeted by the assay, using the GenBank accession AY632535.2 synthesized to a scale of 250 nmol
through HPLC purification.
4.4.3. Histology
Brain and ovary tissues were fixed in 10% neutral-buffered saline and processed to paraffin
wax. Sections of 3–5 µm were stained using hematoxylin and eosin (H&E) to examine by microscope.
Lesions were scored subjectively using the following scale—within normal limits, minimal, moderate,
and marked. The experiment was blinded to prevent bias.
4.4.4. Contributions
ARS and AHP are the grant holders. ARS directed the project and commissioned the work. CLC
designed, constructed, and characterized the adenoviral vaccines. JLSC, MP, and GDL constructed
DNA vaccines and subunit EDIII vaccines, respectively. CLC, PA, RAL, JLSC, GDL, and MP, designed
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and performed the animal experiments. PA and RAL, performed the ZIKV challenge model in the
BALB/c mice and the RT-PCR viral loads. CLC, PA, and RAL performed the ELISA assays and analyzed
the ZIKV challenge data. SD, VG, and RH conceived and designed the animal experiments in A129
mice. SD, VG, ER, and SFW performed the animal experiments, such as the ZIKV challenge model
in A129 mice, the RT-PCR and the histology. MP, GDL, and JLSC performed FRNTs. CLC, JLSC,
RAL, and GDL performed in vitro assays and analyzed the ZIKV challenge data. YCK produced
ZIKV envelope protein and performed ELISA assays. WD and JM designed, performed, and analyzed
in vitro experiments. CLC and MP performed the cell culture, transfections, and the Western blots.
AHP, GRS, DHB, ORB, and ASH provided the vital characterized reagents and conceptual support.
CLC, GDL, and JLSC analyzed all data. CLC and JLSC wrote the initial draft. All authors read and
commented on the manuscript.
5. Conclusions
The Domain III (DIII) of the Zika envelope protein is an attractive antigen currently explored as
an approach for vaccine development. DIII has given promising results when used as a vaccine for
dengue virus and this has prompted its use as a strategy to immunize against the related Zika virus.
We investigated the potential of this protein to elicit protective immunity in various mouse models,
through the use of three different platforms suitable for vaccine development: plasmid DNA, protein
and the chimpanzee adenovirus ChAdOx1. Our results indicate that vaccine-induced immunity to
DIII from Zika virus offers limited protection against a challenge with different Zika virus strains
comprising the Asian and African lineages. Results were obtained in independent laboratories under
different conditions, all yielding similar results of low protective efficacy. We conclude that DIII per
se is not a promising vaccine candidate and alternative candidates need to be assessed to offer better
protection against Zika virus.
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